Additionally, we have shown that the lack in effect in tumor control between mice treated with [177Lu]Lu-PSMA-I&T and olaparib or [177Lu]Lu-PSMA-I&T alone was not caused by insufficient levels of the PARPi to reach the tumor as olaparib levels in tumor and plasma 2 h post-injection were in line with concentrations found previously in CD1 nude mice bearing G7 glioblastoma xenografts 2 h post-injection with 50mg/kg olaparib, which was sufficient to radiosensitize these tumors [25]. This evidence concerns the gene FOLH1 and glioblastoma.